Gilead Sciences GILD Total HIV — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's total hiv — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's total HIV — total revenues?
- Gilead Sciences (GILD) reported total HIV — total revenues of $5.03B in Q1 2026.
- How has Gilead Sciences's total HIV — total revenues changed year-over-year?
- Gilead Sciences's total HIV — total revenues increased by 9.7% year-over-year, from $4.59B to $5.03B.
- What is the long-term trend for Gilead Sciences's total HIV — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's total HIV — total revenues has grown at a 6.2% compound annual growth rate (CAGR), from $16.32B to $20.75B.
- What does total HIV — total revenues mean?
- The total revenue earned from selling HIV-related pharmaceutical products.
- How do you interpret total HIV — total revenues?
- An increase indicates strong market penetration, successful adoption of new drug regimens, or effective pricing strategies within the HIV therapeutic market. A decrease may signal increased generic competition, loss of patent exclusivity, or a shift in patient treatment preferences.
- How does total HIV — total revenues compare across companies?
- Comparable to HIV-specific franchise revenues reported by other major biopharmaceutical companies with significant infectious disease portfolios, such as GSK's ViiV Healthcare segment.